Antimicrobial agents are commonly used after hematopoietic stem cell transplant (HSCT) to prevent bacterial, viral and fungal infections. A pharmacy practice survey was undertaken to evaluate prevailing practices. The 31 centers evaluated transplanted over 3400 patients in 2001. Over half used bacterial prophylaxis; all with fluoroquinolones. A significantly higher proportion (90-100%) used fungal and viral prophylaxis. Most centers used fluconazole for fungal prophylaxis, but the dose used varied from 400 mg (the recommended dose) to 100 mg. Itraconazole and amphotericin preparations were used by some centers for allograft recipients because of their activity against aspergillosis. Most centers used brief viral prophylaxis for autograft recipients aimed at preventing HSV reactivation. Viral prophylaxis for allograft recipients was usually much more prolonged, reflecting concern over cytomegalovirus infections. Overall, there was significant deviation from recommended guidelines in many of the practices. Our survey suggests that substantial variation exists among transplant centers in their approach to antimicrobial prophylaxis after HSCT. This probably stems from the lack of definitive studies and strong recommendations in several areas, availability of newer agents that have not been adequately studied in the HSCT setting, and a desire to improve outcome before definitive studies are available for newer agents, a process that could take several years.
Antimicrobial agents are commonly used prophylactically after hematopoietic stem cell transplantation (HSCT) to prevent bacterial, viral and fungal infections. The studies supporting these practices do not always reach a definitive conclusion in terms of modification of existing clinical practice. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Therefore, guidelines have been formulated for the prevention of infections following HSCT, 14, 15 and have been endorsed by the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation. These evidence-based reviews have made weighted recommendations for the use of antimicrobial agents as prophylaxis for bacterial, viral, and fungal pathogens.
Despite this, our experience has been that significant variations in practice exist between transplant centers. We decided to determine what differences in practice exist between transplant centers, and how these practices conform to the joint guidelines through a pharmacy practice survey.
Methods

One of the authors (ST) is the Pharmacist of the HSCT Program of Northwestern Memorial
Hospital who helps develop drug treatment policies and protocols, and makes daily rounds of in-patients with the transplant team to ensure appropriate therapy. ST developed the concept for the survey, designed the data collection form, and administered the questionnaire to transplant pharmacists during the 2003 Tandem BMT Meeting in Keystone, Colorado. The information solicited included the name of the institution, and prophylactic antimicrobial administration practice separately for autograft, myeloablative allografts, and nonmyeloablative allografts. Information was sought for bacterial, fungal, and viral prophylaxis. For each drug, the dose, and the starting and stopping dates were sought.
The w 2 test and the Fisher's exact test were used to determine the significance of differences between categoric variables.
Results
Pharmacists from 32 transplant centers responded to the survey; 30 from USA, one from Mexico, and one from Saudi Arabia. After review, the 31 from USA and Mexico were considered sufficiently complete to be interpreted and analyzed. Data for the number of transplants undertaken at each institution from USA was collected from the transplant website www.bmtinfonet.com.
The total number of transplants carried out in the 30 institutions from USA in 2001 was just over 3400. The number of transplants per year (for 2001) ranged from 30 to 4400 (median 84). Geographically, the transplant centers were distributed evenly throughout the USA (eight mid-west, eight west, five southeast, five northeast, and four southwest).
Antibacterial agents
All centers used a similar approach for autografts and allografts (Table 1 ). Approximately 60% of the centers use fluoroquinolone prophylaxis, whereas just over 40% use no prophylaxis. Tables 2 and 3 show fungal prophylaxis for autologous and allogeneic HSCT recipients, respectively. The majority (84%) of centers used fluconazole at a dose of 100-400 mg daily for autograft recipients. A couple of centers used itraconazole or amphotericin in an attempt to broaden cover for autografted patients, whereas three centers did not use fungal prophylaxis at all.
Antifungal agents
None of the centers distinguished between conventionaland reduced-intensity allografts or standard-and high-risk allografts. However, the approach to allografts was different from that to autotransplant patients. The proportion of centers not using fungal prophylaxis was not significantly different. However, a lower proportion of those receiving prophylaxis received fluconazole (P ¼ 0.079). Most of those administering prophylaxis continued this beyond neutrophil recovery, usually until immunosuppression was withdrawn, in contrast to autografts where prophylaxis was universally discontinued on neutrophil recovery. Tables 4 and 5 show the results of viral prophylaxis for autologous and allogeneic transplants, respectively. For autotransplant recipients, most centers used prophylaxis, and when prophylaxis was employed, it was with acyclovir or its prodrug valacyclovir. However, the doses used varied widely (Table 4) . Most centers discontinued the drug upon neutrophil recovery as the risk of herpetic stomatitis subsided, but a couple continued the drug for several months as prophylaxis against varicella zoster.
Antiviral agents
All centers employed some viral prophylaxis for allogeneic transplant recipients. While respondents were not asked to stratify responses by cytomegalovirus (CMV) serostatus, the prolonged nature of the prophylaxis employed by most centers suggests CMV as the prime concern. Acyclovir and valacyclovir, at widely variable doses, were used by most centers, although in a minority of instances the approach was targeted specifically towards CMV with prophylactic use of ganciclovir or foscarnet.
Discussion
The results of this study show that there is significant variation in the type of drugs used for antimicrobial prophylaxis in HSCT recipients as well as their dosing and schedules. Since the purpose of the survey was not to document every single prophylactic approach used but rather to illustrate variation, we feel the sample size of 31 centers with approximately 3400 transplants annually reflects the overall situation -heterogeneity of approachfairly well. Since clinical outcomes were not studied, it is unclear if the differences in practice are practically significant. Even if crude outcome data were available, it is very likely that the influence of a number of other important patient-, disease-, and therapy-related variables would make interpretation of any differences difficult. The practice at each institution was identical for autografts and allografts. All drugs are administered orally unless otherwise specified. Percent total comes to 101 because of rounding. All drugs are administered orally unless otherwise specified.
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It is interesting to see that a significantly lower proportion of centers used bacterial prophylaxis compared with fungal (P ¼ 0.008 for autografts, P ¼ 0.001 for allografts) or viral (P ¼ 0.002 for autografts, Po0.001 for allografts) prophylaxis. Presumably, with much-shortened durations of pancytopenia, bacterial infections are not perceived to be a concern. Additionally, at least partly because of the shortened neutropenia, the guidelines do not make a definitive statement on antibacterial prophylaxis ('No recommendations can be made regarding routine use of antibacterial prophylaxis in afebrile, asymptomatic patients').
14 Discussion with respondents using fluoroquinolone prophylaxis suggested concern for the overwhelming nature of gram-negative septicemia, historical guidelines/practice, and hospital pharmacy and therapeutics committee recommendations as reasons for drug use. Cost of drugs, the joint guidelines, and concern about drug resistance were cited as reasons for not using prophylaxis by those not employing fluoroquinolones. It is interesting to note that the use of trimethoprim-sulfamethoxazole for gut decontamination, once a widely prevalent practice, appears to have been eliminated. /l (n ¼ 1)
Absolute neutrophil count X0.5 Â 10 9 /l; then switch to fluconazole until discontinuation of immunosuppression 2 (6) None
All drugs are administered orally unless otherwise specified. /l (n ¼ 1), day +45 (n ¼ 1), day +180 (n ¼ 1) 2 (7) None All drugs are administered orally unless otherwise specified. One respondent did not answer. All drugs are administered orally unless otherwise specified. One respondent did not answer.
For fungal prophylaxis, current guidelines suggest the use of fluconazole at the dose of 400 mg/day for allograft recipients and autograft recipients with a potential for prolonged neutropenia.
14 In practice, half the respondents use the recommended schedule of fluconazole for autografts and allografts. A substantial proportion of centers uses lower doses for autograft recipients because of newer data and cost concerns. Those who do use fluconazole for autografts do not distinguish between those at a high risk of prolonged neutropenia and others.
The guidelines do not make any definitive recommendations for prophylaxis against mold infections in allograft recipients because of lack of data. However, as Table 3 shows, about 25% of the centers do use prophylactic regimens with putative action against Aspergillus spp. Interestingly, although it was not part of this survey, in a group discussion on treatment of confirmed Aspergillus infections, the majority of centers were inclined to use a two-drug combination from the three of the four available active agents (caspofungin, amphotericin, and voriconazole; itraconazole used for prophylaxis but not for therapy) from the start even though there is no evidence in the literature to support this practice. This very likely reveals lack of satisfaction with the results of standard practice (single agent therapy) and a willingness to explore aggressive strategies to improve outcome.
The guidelines suggest that all HSV-seropositive patients be given acyclovir to prevent HSV reactivation from the start of the conditioning regimen for approximately 30 days (which would allow for the resolution of neutropenia as well as oral mucositis), although a dose has not been specified. Long-term acyclovir prophylaxis has been suggested for patients with frequent HSV recurrences and for patients with prolonged, severe immunodeficiency to prevent herpes zoster. The guidelines recommend preemptive ganciclovir for CMV control rather than prophylaxis. Neither acyclovir nor valacyclovir are recommended for CMV prophylaxis in the guidelines although the potential efficacy of high-dose acyclovir in reducing the risk of CMV disease in allograft recipients is acknowledged. As Table 4 shows, virtually all programs use prophylaxis against HSV in autograft recipients as generally recommended in the guidelines. Two centers (ours is one) use prolonged acyclovir for protection against varicella zoster reactivation. Our observation (unpublished) is that this is 100% effective in preventing herpes zoster during a period when as many as 20% of patients develop zoster. Two-thirds of the centers continued viral prophylaxis for a prolonged period in allograft recipients, whereas one-third stopped prophylaxis fairly early as recommended in the guidelines. The doses used by the centers administering prolonged viral prophylaxis are higher than those used for autograft recipients, suggesting that the aim was probably to prevent CMV. There is a possibility that one of the respondents made a mistake ( Table 5 ) in saying that intravenous ganciclovir was employed from the start of the conditioning to the discontinuation of immunosuppression. However, all other answers from this respondent were straightforward, and no post facto clarifications were sought from any of the respondents.
Other reasons that could account for variations in practice to a smaller extent may include familiarity with certain agents, local protocols, and variable costs of drug acquisition depending upon institutional contracts with suppliers.
We conclude that a variety of drugs, doses, and schedules are used in practice for the prevention of infection in HSCT patients. There are significant differences between clinical practice and guidelines. It appears that experience, and hope for improved patient care are guiding practitioners through the ever-changing labyrinth of antimicrobial prophylaxis. We hope that the results of ongoing and future randomized studies will broaden the consensus in this area of concern.
